SEC Tracker
Get the app

Entera Bio ENTX

Entera Bio appoints Laura Hamill as director

Form
8-K
Filed
Importance
Major
  1. Laura Hamill appointed as Class I director effective Dec 1, 2026
  2. Yonatan Malca steps down as director effective Dec 1, 2026
  3. Ms. Hamill has 35+ years of biopharma commercial experience
  4. Ms. Hamill joins boards of Jazz Pharmaceuticals, BB Biotech AG, and Fate Therapeutics

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Entera Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Instil Bio TIL public float $83M, Jun 30, 2025
  2. Coherus Oncology CHRS public float $82M, Jun 30, 2025
  3. SAB Biotherapeutics SABS public float $77M, Jun 30, 2025
  4. Vor Biopharma VOR public float $76M, Jun 30, 2025
  5. Jasper Therapeutics JSPR public float $75M, Jun 30, 2025